Inflammation and Negative Symptoms of Schizophrenia: Implications for Reward Processing and Motivational Deficits

Frontiers in Psychiatry
David R Goldsmith, Mark Hyman Rapaport

Abstract

Negative symptoms of schizophrenia are debilitating and chronic in nature, are difficult to treat, and contribute to poor functional outcomes. Motivational deficits are a core negative symptom and may involve alterations in reward processing, which involve subcortical regions such as the basal ganglia. More specifically, dopamine-rich regions like the ventral striatum, have been implicated in these reward-processing deficits. Inflammation is one mechanism that may underlie negative symptoms, and specifically motivational deficits, via the effects of inflammatory cytokines on the basal ganglia. Previous work has demonstrated that inflammatory stimuli decrease neural activity in the ventral striatum and decrease connectivity in reward-relevant neural circuitry. The immune system has been shown to be involved in the pathophysiology of schizophrenia, and inflammatory cytokines have been shown to be altered in patients with the disorder. This paper reviews the literature on associations between inflammatory markers and negative symptoms of schizophrenia as well as the role of anti-inflammatory drugs to target negative symptoms. We also review the literature on the role of inflammation and reward processing deficits in both healthy c...Continue Reading

References

Jul 11, 1998·Journal of Neurophysiology·W Schultz
Feb 15, 2001·Archives of General Psychiatry·B KirkpatrickW T Carpenter
Feb 24, 2001·Autonomic Neuroscience : Basic & Clinical·L E GoehlerL R Watkins
Jun 4, 2002·The American Journal of Psychiatry·Norbert MüllerMarkus J Schwarz
May 11, 2004·Social Psychiatry and Psychiatric Epidemiology·Steven Marwaha, Sonia Johnson
May 25, 2004·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Samuel M McClureP Read Montague
Nov 9, 2004·Trends in Pharmacological Sciences·María Domercq, Carlos Matute
Jun 15, 2005·Biological Psychiatry·Mark Hyman RapaportDouglas Dolnak
Sep 6, 2005·NeuroImage·Georg JuckelAndreas Heinz
Oct 11, 2005·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Lorraine MarnellTerry W Du Clos
Oct 29, 2005·Schizophrenia Bulletin·Jack J Blanchard, Alex S Cohen
Dec 22, 2005·Current Medical Research and Opinion·R GoereeJ-E Tarride
Feb 17, 2006·Schizophrenia Bulletin·Brian KirkpatrickStephen R Marder
Mar 4, 2006·The American Journal of Psychiatry·William W EatonPreben Bo Mortensen
Jul 3, 2007·Brain, Behavior, and Immunity·Ning Quan, William A Banks
Aug 7, 2007·Biological Psychiatry·Jennifer C FelgerAndrew H Miller
Aug 9, 2007·Molecular Psychiatry·G K MurrayP C Fletcher
Nov 21, 2007·The British Journal of Psychiatry. Supplement·Iain KooymanElizabeth Walsh
Sep 11, 2008·Current Drug Metabolism·G NeurauterD Fuchs
Oct 7, 2008·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Brian Kirkpatrick, Silvana Galderisi
Dec 20, 2008·Schizophrenia Bulletin·Gregory P StraussCherise Rosen
Jan 22, 2009·Schizophrenia Bulletin·Klaas E StephanChris D Frith
Jan 30, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Thomas W WeickertVenkata S Mattay
Feb 7, 2009·Biological Psychiatry·Florian SchlagenhaufAndreas Heinz
Feb 21, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Charlotte D'MelloMark G Swain
Mar 28, 2009·Schizophrenia Bulletin·Oliver D Howes, Shitij Kapur
Apr 16, 2009·The International Journal of Neuropsychopharmacology·Catherine Bresee, Mark H Rapaport
May 5, 2009·Biological Psychiatry·Neil A HarrisonHugo D Critchley
Feb 4, 2010·The American Journal of Psychiatry·Alan S Brown, Elena J Derkits
Jun 19, 2010·Schizophrenia Bulletin·Brian KirkpatrickStephen R Marder
Jul 3, 2010·The American Journal of Psychiatry·Thomas InselPhilip Wang
Jul 16, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Mary-Ellen LynallEd Bullmore
Aug 20, 2010·Biological Psychiatry·Naomi I EisenbergerMichael R Irwin
Feb 8, 2011·Biochimica Et Biophysica Acta·Jürgen SchellerStefan Rose-John
Jun 7, 2011·Biological Psychiatry·Brian J MillerBrian Kirkpatrick

❮ Previous
Next ❯

Citations

Dec 22, 2020·Focus : Journal of Life Long Learning in Psychiatry
Aug 10, 2021·Frontiers in Psychiatry·Alex J MurrayRachel Upthegrove
Aug 28, 2021·Journal of Clinical Medicine·Juan L Prados-OjedaAlejandro Escudero-Contreras

❮ Previous
Next ❯

Methods Mentioned

BETA
Assay
ELISA
pharmacotherapy
enzyme-linked immunosorbent assay

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here